Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6854—Immunoglobulins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
  • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
  • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
  • G01N33/5047—Cells of the immune system
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
  • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/575—Hormones
  • G01N2333/635—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
  • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
  • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
  • G01N2333/70592—CD52
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N2800/00—Detection or diagnosis of diseases
  • G01N2800/04—Endocrine or metabolic disorders
  • G01N2800/046—Thyroid disorders

Definitions

• T4 L-thyroxine
• T3 L-triiodothyronine
• T3 L-thyroxine
• T3 L-triiodothyronine
• T3 L-thyroxine
• T3 L-triiodothyronine
• Untreated, severe hypothyroidism is characterized by weight gain, low energy and depression, intolerance of cold, and changes in skin and hair.
• Untreated, severe hyperthyroidism presents as a state called thyrotoxicosis, characterized by weight loss, nervousness or emotional instability, intolerance of heat, tremor, and a rapid heart rate, and can cause cardiac atrial fibrillation.
• hypothyroidism or hyperthyroidism may occur with no discernible symptoms or signs despite abnormal findings on laboratory tests of thyroid function (e.g., a subclinical thyroid disorder).
• T3 and T4 are produced under direct control by the anterior pituitary glycoprotein hormone thyrotropin (thyroid stimulating hormone, TSH), which is itself regulated by the hypothalamic hormone thyrotropin releasing hormone (TRH). TSH acts through a membrane-bound G-protein coupled receptor (TSH-R) to activate the major thyroidal functions. Synthesis of T3 and T4 requires incorporation of iodide into their precursor. Thyroid peroxidase (TPO) is a membrane-bound, glycosylated heme-containing enzyme that catalyzes both the iodination of tyrosyl residues and the coupling of iodotyrosyl residues in thyroglobulin to form T3 and T4. Once synthesized, T3 and T4 are stored in a colloidal form on the protein thyroglobulin (Tg) prior to release of the hormones.
• Tg protein thyroglobulin
• TPO TSH-R
• Tg proteins may become autoantigens, i.e., targets for autoimmune responses most easily identified by the auto-antibodies that bind these proteins.
• antibodies reactive with the microsomal fraction of thyroid tissue were also detected and studied.
• thyroid peroxidase was found to be the chief target for such anti-thyroid microsomal antibodies.
• thyroid microsomal antibodies and thyroid peroxidase antibodies have been considered to be essentially equivalent terms.
• TSHRA The signaling function of the TSH-R protein normally becomes activated only upon binding of thyrotropin.
• TSHRA antibodies directed against the TSH-R
• this class of TSHRA autoantibody can act as a direct agonist (stimulating antibody) or antagonist (blocking antibody) of the TSH-R.
• thyroid autoimmunity can be associated with aberrant regulation of thyroid hormone secretion and cause either hypo- or hyper-thyroidism.
• TSHRA Trigger's syndrome
• TPOA Antibodies directed against TPO
• patients with this disorder may present clinically with either hypo- or hyper-thyroidism, and a given patient may at different times manifest both conditions.
• the disorder may involve other tissues.
• Graves' ophthalmopathy In Graves' ophthalmopathy (technically an orbitopathy, because the changes are confined to orbital structures and spare the internal structure of the eye), enlargement of the extraocular muscle bundles and adipose hypertrophy cause protrusion of the eyeball (exophthalmos or proptosis) resulting in double vision (diplopia) and, in severe cases, visual loss.
• Hyperthyroid Grave's disease can often be managed with oral thyroid suppressant drugs, such as methimazole or propylthiouracil. Refractory cases may require thyroid ablation using radioactive iodine or a surgical thyroidectomy. With thyroid suppression, the patient will require thyroid replacement hormone. Severe ophthalmopathy may require radiation therapy delivered to the orbits or surgical decompression of the orbit.
• TPOA TPOA
• thyroid disorders occur frequently among patients who receive interferon-alpha therapy for hepatitis C virus infection (Preziati, D., et al., Eur J Endocrinol, 132(5)587-93 (1995)).
• pretreatment antibodies to TPO or to thyroid microsomal fraction appear to be a marker for increased risk of hyper- and hypothyroid disorders among patients who subsequently receive interferon-alpha therapy (Marazuela, M., et al., Clin Endocrinol 44:635-42 (1996); Watanabe, U., et al., Am J Gastroenterol, 89(3):399-403 (1994); Femandez-Soto, L., et al., Arch Intern Med, 158:1445-1448 (1998)).
• TPOA detected during pregnancy appear to predict risk for post-partum thyroid disorders (Vargas, M. T., et al., J. Clin. Endocrinol. Metab., 67(2):327-33 (1988)).
• alemtuzumab Treatment of a person with alemtuzumab using an appropriate dosage and regimen will, among other effects, result in prompt and relatively sustained depletion from the bodily tissues and blood of normal and neoplastic lymphocytes while sparing the haemopoietic stem cells that are needed to repopulate the immune system.
• Alemtuzumab is disclosed in US patent U.S. Pat. No. 5,846,534.
• Alemtuzumab is approved for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy.
• B-CLL B-cell chronic lymphocytic leukemia
• Clinical studies have shown that alemtuzumab is also active in other hematologic malignancies such as non-Hodgkin's lymphoma and leukemias, and in a variety of immune mediated disorders including graft-versus-host disease, organ transplant rejection, rheumatoid arthritis, and, notably multiple sclerosis (Hale G. and Waldmann H., From laboratory to clinic: the story of CAMPATH-1. In: George A J T, Urch C E, eds. Methods in Molecular Medicine: Diagnostic and Therapeutic Antibodies. NJ: Humana Press; 2000; 40:243-266).
• alemtuzumab was administered at two dose levels (a five day course of 12 mg or 24 mg/day for cumulative doses of 60 or 120 mg in the first year, followed by a three-day course of 12 mg or 24 mg/day for cumulative doses of 36 or 72 mg in the second year, with possible retreatment similarly using 36 or 72 mg in the third year).
• patients on the control arm received interferon beta-1a (Rebif®; EMD Serono, Inc.) 44 mcg subcutaneously (SC) three times per week as indicated in the product label (O'Donnell, L, et al, Presented at the Consortium of Multiple Sclerosis Centers Annual Meeting, Toronto, Canada, Jun.
• alemtuzumab was more effective than interferon beta-1a (Rebif®; EMD Serono, Inc.), a licensed treatment for MS, in reducing the risk of MS relapse and in slowing the accrual of sustained disability.
• alemtuzumab regimen experienced at least a 75% reduction in the risk for relapse after at least one- and two-years of follow-up when compared to patients treated with interferon beta-1a.
• the alemtuzumab-treated patients additionally experienced at least a 60% reduction (relative to Rebif®-treated patients) in the risk for the sustained accumulation of disability after 1 year, and at least a 65% reduction in that risk after 2 years.
• Delayed onset of thyroid disorders also occurs in other circumstances characterized by lymphocyte depletion and repopulation, notably delayed onset of thyroid disorders following bone marrow transplantation, whether autologous or allogeneic, and whether for treatment of primary immunodeficiency or for reconstitution after iatrogenic bone marrow suppression (Ishiguro H., et al., J Clin Endocrinol Metab, 89(12):5981-6 (2004); Slatter M. A., et al., Bone Marrow Transplant., 33(9):949-53 (2004); Carlson K., et al., Bone Marrow Transplant., 10(2):123-7. (1992); Lee W.
• alemtuzumab appears to be an effective treatment for patients with a variety of disorders, but its use in MS but has been associated with auto-immune complications including thyroid glandular disorders. Similar complications occur with other lymphocyte depleting therapies. In some individuals, the benefit from therapeutic regimens involving lymphocyte depletion may be offset by adverse effects. Thus, in order to maximize the benefit-to-risk ratio attending the use of a lymphocyte depleting therapy such as alemtuzumab in patients (e.g., MS patients), it would be desirable to have a means for identifying (e.g., prior to the initiation of alemtuzumab treatment) those individuals who are at increased risk for autoimmune thyroid disorders. Such prediction of risk would be useful to support informed medical decision making, e.g., whether or not to initiate treatment with a lymphocyte depleting regimen in a given individual based on the predicted risk for this adverse effect.
• the invention relates to a method for predicting the risk for thyroid glandular disorders that may occur in a patient as a complication of therapeutic regimens that deplete lymphocytes (a lymphocyte depleting regimen).
• the method is based on detecting the presence or absence of autoantibodies in the patient prior to receiving a first or subsequent course of the lymphocyte depleting regimen (e.g., prior assessment of autoantibodies in the blood).
• a lymphocyte depleting regimen e.g., prior assessment of autoantibodies in the blood.
• blood testing prior to alemtuzumab treatment allows for the prediction of risk for thyroid disorders that can occur following alemtuzumab treatment.
• the invention is based in part on the discovery that MS patients who have antibodies directed against the thyroid peroxidase enzyme (TPO) prior to or at the time of initial treatment with alemtuzumab are at increased risk for developing thyroid disorders subsequent to such treatment.
• TPO thyroid peroxidase enzyme
• the invention involves a method of determining patients at relatively higher risk for developing a thyroid disorder subsequent to treatment with a therapeutic regimen that depletes lymphocytes (and also perhaps depletes other cell types), comprising the step of assaying a biological sample from the patient for antibodies directed against thyroid peroxidase (TPOA).
• TPOA thyroid peroxidase
• the invention involves a method of determining patients at relatively higher risk for developing a thyroid disorder subsequent to treatment with a therapeutic regimen that depletes cells which bear CD52 as a surface marker (i.e., CD52-positive cells), comprising the step of assaying a biological sample from the patient for antibodies directed against thyroid peroxidase (TPOA).
• TPOA thyroid peroxidase
• a “regimen which depletes CD52-positive cells” includes any molecule which depletes, partially or completely, human cells bearing the CD52 marker.
• an agent that depletes CD52-positive cells includes, without limitation, an antibody, a small interfering RNA or a small molecule that reduces the count of CD52-bearing cells from blood circulation and/or bodily tissues.
• the therapeutic regimen that depletes CD52-positive cells will, in particular embodiments, involve administration of an antibody that binds specifically to CD52. In some embodiments, it is a human or a humanized anti-CD52 antibody such as or similar to alemtuzumab (Campath®, MabCampath®, Campath-1H®).
• the invention in another embodiment, relates to a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder subsequent to treatment with a regimen that depletes lymphocytes (e.g., treatment with an agent that depletes CD52-positive cells, such as alemtuzumab), comprising determining whether antibodies directed against thyroid peroxidase are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing a thyroid disorder subsequent to treatment.
• a regimen that depletes lymphocytes e.g., treatment with an agent that depletes CD52-positive cells, such as alemtuzumab
• the methods described herein are applicable to patients with relapsing remitting multiple sclerosis as well as primary and secondary progressive multiple sclerosis.
• the invention involves a method of determining patients at relatively higher risk for developing a thyroid disorder subsequent to treatment, where that treatment involves a therapeutic regimen that produces iatrogenic lymphocyte depletion as an accompaniment to the desired therapeutic effect.
• a therapeutic regimen that produces iatrogenic lymphocyte depletion as an accompaniment to the desired therapeutic effect.
• Such regimens include, without limitation, those that involve administration of one or more cytotoxic chemotherapy agents as for treatment of neoplasia, autoimmunity, or preparatory to bone marrow or solid organ transplantation; and the administration of anti-thymocyte globulin (e.g., Thymoglobulin®) intended to deplete T lymphocytes for suppression of organ transplant rejection.
• cytotoxic chemotherapy agents as for treatment of neoplasia, autoimmunity, or preparatory to bone marrow or solid organ transplantation
• anti-thymocyte globulin e.g., Thymoglobulin®
• the methods of the invention will be useful for predicting the risk of a thyroid disorder developing in a patient subsequent to treatment with any therapeutic regimen that depletes lymphocytes, while other cell types may or may not be depleted by the treatment.
• the total lymphocyte population comprises subsets, chiefly T cells, B cells, and NK cells.
• the therapeutic regimen that depletes lymphocytes is a regimen targeted against T lymphocytes.
• it is a regimen targeted against B lymphocytes.
• it is a regimen targeted against NK cells.
• it is a regimen targeted against various combinations of T and B lymphocytes and NK cells (e.g., T and B and NK; T and B but not NK; etc.).
• Foreknowledge of the risk for developing thyroid disorders associated with lymphocyte depletion is useful to support informed medical decision making, e.g., whether or not to initiate treatment with a lymphocyte depleting regimen in a given patient based on the predicted risk for the development of a thyroid disorder.
• Tests to determine whether antibodies directed against thyroid peroxidase are present in the patient may be performed prior to, or after, treatment with the regimen that depletes lymphocytes. Ideally, the test for TPOA is performed prior to a given course of treatment so that knowledge of the potential risks of treatment may be considered by the doctor and patient in making treatment decisions. However, knowledge of the presence of TPOA is also useful subsequent to treatment as an early indicator for increasing risk.
• Autoimmune thyroid disorders that may occur as a result of treating a patient with a lymphocyte depleting therapy may manifest as either hypothyroidism or hyperthyroidism.
• Common diagnoses include Graves' Disease (also known as diffuse toxic goiter, von Basedow's disease, or Parry's disease) and autoimmune thyroiditis (also known as silent thyroiditis or Hashimoto's thyroiditis) and combinations thereof.
• Antibodies directed against thyroid peroxidase are usually sought in a blood sample (commonly serum or plasma) obtained from the patient, but might be detected in any biological sample obtained from the patient, including lymph, urine and/or tissue.
• a blood sample commonly serum or plasma
• any biological sample obtained from the patient including lymph, urine and/or tissue.
• ELISA enzyme-linked immunosorbent assays
• RIA radioimmunoassays
• hemagglutination assays various other techniques that employ a form or fragment of the thyroid peroxidase protein as a target intended to attract and bind to the antibodies to be measured, and employing any method appropriate to detect and perhaps quantitate the bound antibodies.
• CAMMS223 is the name for a Phase 2 clinical trial investigating the safety and efficacy of two dose levels of alemtuzumab in comparison with interferon beta-1a (Rebif®) in the treatment of patients with early, active, relapsing-remitting MS.
• Patients referred for participation in CAMMS223 were screened for anti-thyroid-stimulating hormone (TSH)-receptor antibodies (hereafter, TSHRA) before entry and excluded if positive.
• TSHRA anti-thyroid-stimulating hormone
• TPOA anti-thyroid peroxidase antibodies
• IFN-beta-1a 44 mcg SC thrice weekly
• alemtuzumab high-dose 24 mg/day intravenously (IV)
• low-dose (12 mg/day IV).
• Alemtuzumab was given daily for 5 days at Month 0 and for 3 days at Month 12 and, for some patients, again at Month 24.
• TSH thyroid-related hormones and thyroid autoantibodies tested at regular intervals: TSH, L-thyroxine (T3) and L-triiodothyronine (T4) and TSHRA were tested quarterly, and thyroid peroxidase antibody (TPOA) were tested twice yearly.
• TPOA thyroid peroxidase antibody
• the proportion of alemtuzumab-treated patients with thyroid clinical AEs was 11.1% versus 1.9% in patients who had received IFN-beta-1a. More thyroid AEs occurred in the low-dose arm but this difference between alemtuzumab doses was not significant.
• Graves' disease or hyperthyroidism was reported in 14/216 alemtuzumab-treated patients (6.5%), and in 0/106 IFN-beta-1a-treated patients (p ⁇ 0.0001).
• TSHRA were found in 47/216 (21.8%) patients after alemtuzumab and 2/103 (1.9%) after IFN-beta-1a.
• Laboratory markers of thyroid autoimmunity occurred without clinical thyroid AEs in 16.7% of patients after treatment with alemtuzumab versus 11.3% of patients treated with IFN-beta-1a.
• TPOA test appears to have a fairly high specificity but low sensitivity. This could reflect poor TPOA assay sensitivity or may indicate that some patients are at risk for alemtuzumab-related thyroid disorders despite an absence of TPOA at baseline.
• the invention encompasses methods for identifying a patient that is at risk for developing a thyroid disorder subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing a thyroid disorder subsequent to treatment.
• Lymphocytes are white blood cells formed in lymphatic tissue of an individual and divided into three principle groups: T cells, B cells, and NK cells.
• the regimen depletes T cells.
• the regimen depletes B cells.
• the regimen depletes NK cells.
• the regimen depletes various combinations of T and B and NK cells.
• the regimen includes any treatment plan that results in a partial or complete deletion of a patient's lymphocytes during or after treatment.
• the regimen comprises the administration of one or more cytotoxic agents (e.g., drugs).
• the regimen comprises administration of an agent that depletes cells expressing CD52 as a cell surface marker (i.e., CD52-positive cells).
• the invention encompasses methods for identifying a patient that is at risk for developing a thyroid disorder subsequent to treatment with an agent that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing a thyroid disorder subsequent to treatment.
• the invention relates to a method for identifying an MS patient that is at risk for developing a thyroid disorder subsequent to treatment with an agent that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder.
• a “regimen which depletes CD52-positive cells” includes any regimen which depletes, partially or completely, human cells bearing the CD52 marker.
• a regimen that depletes CD52-positive cells includes, without limitation, administration of an antibody, a small interfering RNA or a small molecule that reduces the count of CD52-bearing cells from blood circulation and/or bodily tissues.
• an agent that depletes CD52-positive cells is an antibody that is specific for CD52.
• An antibody that is specific for CD52 is a molecule that selectively binds to CD52 but does not substantially bind to other molecules in a sample, e.g., in a biological sample that contains CD52.
• the term “antibody,” as used herein, refers to an immunoglobulin or a part thereof, and encompasses any polypeptide comprising an antigen-binding site regardless of the source, method of production, and other characteristics.
• antigen-binding site refers to the part of an antibody molecule that comprises the area specifically binding to or complementary to, a part or all of an antigen.
• An antigen-binding site may comprise an antibody light chain variable region (V L ) and an antibody heavy chain variable region (V H ).
• An antigen-binding site may be provided by one or more antibody variable domains (e.g., an Fd antibody fragment consisting of a V H domain, an Fv antibody fragment consisting of a V H domain and a V L domain, or an scFv antibody fragment consisting of a V H domain and a V L domain joined by a linker).
• antibody variable domains e.g., an Fd antibody fragment consisting of a V H domain, an Fv antibody fragment consisting of a V H domain and a V L domain, or an scFv antibody fragment consisting of a V H domain and a V L domain joined by a linker.
• anti-CD52 antibody or “antibody against CD52,” refers to any antibody that specifically binds to at least one epitope of CD52.
• the various antibodies and portions thereof can be produced using any of a variety of techniques (see, e.g., Kohler and Milstein, Nature 256:495-497 (1975); Current Protocols in Immunology, Coligan et al., (eds.) John Wiley & Sons, Inc., New York, N.Y. (1994); Cabilly et al., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent No. 0,125,023 B1; Boss et al., U.S. Pat. No. 4,816,397; Boss et al., European Patent No. 0,120,694 B1; Neuberger, M. S.
• the CD52 antibody is alemtuzumab, a recombinant DNA-derived humanized monoclonal antibody that is directed against CD52.
• alemtuzumab a recombinant DNA-derived humanized monoclonal antibody that is directed against CD52.
• the sequence of alemtuzumab (Campath-1H®), including the sequence of the three CDRs contained therein, is disclosed in U.S. Pat. No. 5,846,534, wherein a humanized antibody which binds effectively to the antigen CD52 as well as a method of treating a human patient having a lymphoid malignancy with such an antibody is described. Procedures for preparation and testing of such an antibody are also disclosed.
• conditions that have been treated with alemtuzumab include hematologic malignancies such as B-cell chronic lymphocytic leukaemia (B-CLL), non-Hodgkin's lymphoma and leukemias, as well as a variety of immune mediated disorders including graft-versus-host disease, organ transplant rejection, vasculitis, uveitis, scleroderma, autoimmune cytopenias and rheumatoid arthritis.
• B-CLL B-cell chronic lymphocytic leukaemia
• non-Hodgkin's lymphoma and leukemias
• immune mediated disorders including graft-versus-host disease, organ transplant rejection, vasculitis, uveitis, scleroderma, autoimmune cytopenias and rheumatoid arthritis.
• the method of the invention is not limited to being performed on patients with these particular diseases. Rather, it is useful for patients with any disease, so long as such disease is am
• Autoimmune thyroid disorders that may occur as a result of treating a patient with a lymphocyte depleting therapy may manifest as either hypothyroidism or hyperthyroidism.
• Common diagnoses include Graves' Disease (also known as diffuse toxic goiter, von Basedow's disease, or Parry's disease) and autoimmune thyroiditis (also known as silent thyroiditis or Hashimoto's thyroiditis) and combinations thereof.
• Tests to determine whether antibodies directed against thyroid peroxidase are present in a patient may be performed prior to, or after, treatment with the lymphocyte depleting regimen. Ideally, the presence of antibodies is determined prior to an initial course of treatment so that knowledge of the potential risks of treatment may be considered by the doctor and patient and weighed against the benefits of treatment. However, it will also be useful to perform the methods of the invention subsequent to the initial treatment of a patient, e.g., in order to determine the risk/benefit of a subsequent course of treatment or in order to monitor for any increasing risk of development of a thyroid disorder at any time subsequent to treatment.
• the blood sample to be analyzed is precisely diluted and applied to the coated substrate for a period of time, during which TPOA antibodies in the blood sample will bind to the plastic because of their interaction with the TPO adherent to this substrate.
• a reagent is added that will recognize and stick to any bound antibody, notably including TPOA.
• This reagent is engineered to have a dual function: in addition to binding with antibodies, it can provide a signal (usually chromogenic or chemiluminescent) in proportion to the amount bound. Thus, the signal indicates indirectly the amount of TPOA in the original sample.
• a variety of methods for detecting antibodies directed against thyroid peroxidase are known to those of skill in the art, and some have been widely used, such as radioimmunoassay (Kung, V. T. et al., Clin. Chem., 27(1):39-42(1981); haemagglutination assay (Marazuela, et al, supra); and the Immulite 2000 Anti-TPO Ab immunoassay with chemiluminescent detection, sold by Siemens Medical Solutions Diagnostics. These and various other techniques have in common that they employ a form or fragment of the thyroid peroxidase protein as a target intended to attract and bind to the antibodies to be measured, and employing any method appropriate to detect and perhaps quantitate the bound antibodies. In another embodiment, the various methods described above and other similar methods are employed to detect antibodies reactive with thyroid microsomes, a tissue fraction that is enriched in the thyroid peroxidase enzyme protein.
• the methods described herein can further comprise comparing the amount (level, titer) of antibodies directed against thyroid peroxidase (TPOA) present in the patient to the amount of TPOA in a suitable control sample.
• the control sample may be taken from an individual who is not believed to be at risk for developing a thyroid disorder (e.g., a sample from a healthy individual).
• the control sample could be taken from a patient with the same or similar disease condition who is administered an alternative treatment regimen which is not lymphocyte depleting, which alternative regimen is not associated with an increased risk of thyroid disorders.
• the measurement of TPOA may be compared with a validated standard not based on a control biological sample, e.g., a diluent or other solution not expected to yield a positive test result.
• a qualitiative method involving an indirect non-competitive enzyme immunoassay specific for the TPO protein was employed for the TPOA measurements described in Example 2.
• the method involved the use of a commercially available kit (Varelisa) TPO antibodies test, manufactured by Phadia GmbH (formerly Sweden Diagnostics) and distributed by Somagen, catalogue number 12396.
• patient serum samples were diluted 1/100 using the provided diluent, and 100 microliters of diluted sample was placed into a plastic well previously coated with purified TPO protein. The sample was allowed to incubate for 30 minutes, and then washed 3-5 times with 300 microliters of provided wash solution.
• HRP horseradish peroxidase
• IgG anti-immunoglobulin G
• TSH thyroid peroxidase antibodies
• free T3, free T4, and TSHRA were tested quarterly, and anti-thyroid peroxidase (TPOA) twice yearly in all patients, using the testing protocol and kit described in Example 1.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Urology & Nephrology (AREA)
• Molecular Biology (AREA)
• Hematology (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Cell Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Physics & Mathematics (AREA)
• Microbiology (AREA)
• Pathology (AREA)
• Biochemistry (AREA)
• Analytical Chemistry (AREA)
• Physics & Mathematics (AREA)
• Food Science & Technology (AREA)
• Biotechnology (AREA)
• Organic Chemistry (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Veterinary Medicine (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Tropical Medicine & Parasitology (AREA)
• Toxicology (AREA)
• Transplantation (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Ophthalmology & Optometry (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (1)

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=39434244

Family Applications (3)

Family Applications After (2)

Country Status (22)

Cited By (2)

Families Citing this family (6)

Citations (4)

Family Cites Families (11)

• 2008
  • 2008-02-15 SI SI200831753A patent/SI2130044T1/sl unknown
  • 2008-02-15 DK DK08725657.4T patent/DK2130044T3/en active
  • 2008-02-15 PT PT87256574T patent/PT2130044T/pt unknown
  • 2008-02-15 EP EP12176625A patent/EP2538217A1/en not_active Withdrawn
  • 2008-02-15 LT LTEP08725657.4T patent/LT2130044T/lt unknown
  • 2008-02-15 HU HUE08725657A patent/HUE031421T2/hu unknown
  • 2008-02-15 MX MX2009008642A patent/MX2009008642A/es active IP Right Grant
  • 2008-02-15 CN CN200880012149.4A patent/CN101657721B/zh active Active
  • 2008-02-15 US US12/526,129 patent/US20100136587A1/en not_active Abandoned
  • 2008-02-15 WO PCT/US2008/002047 patent/WO2008103292A1/en active Application Filing
  • 2008-02-15 ES ES08725657.4T patent/ES2612558T3/es active Active
  • 2008-02-15 JP JP2009549628A patent/JP5662684B2/ja active Active
  • 2008-02-15 CA CA002678199A patent/CA2678199A1/en not_active Withdrawn
  • 2008-02-15 CN CN201810058824.2A patent/CN108303546B/zh active Active
  • 2008-02-15 EP EP08725657.4A patent/EP2130044B1/en active Active
  • 2008-02-15 AU AU2008219097A patent/AU2008219097B2/en active Active
  • 2008-02-15 BR BRPI0807601A patent/BRPI0807601B8/pt active IP Right Grant
  • 2008-02-15 RS RS20170083A patent/RS55636B1/sr unknown
  • 2008-02-15 PL PL08725657T patent/PL2130044T3/pl unknown
• 2009
  • 2009-08-10 IL IL200314A patent/IL200314A/en active IP Right Grant
• 2012
  • 2012-12-05 US US13/705,944 patent/US9664688B2/en active Active
• 2013
  • 2013-05-06 RU RU2013120485/15A patent/RU2013120485A/ru not_active Application Discontinuation
• 2014
  • 2014-05-28 JP JP2014110361A patent/JP6058585B2/ja active Active
• 2015
  • 2015-11-02 IL IL242391A patent/IL242391A/en active IP Right Grant
• 2017
  • 2017-01-25 HR HRP20170121TT patent/HRP20170121T1/hr unknown
  • 2017-01-26 CY CY20171100113T patent/CY1118663T1/el unknown
  • 2017-05-10 US US15/591,547 patent/US10648986B2/en active Active
• 2018
  • 2018-12-27 HK HK18116630.2A patent/HK1257419A1/zh unknown

Patent Citations (4)

Non-Patent Citations (3)

Also Published As

Similar Documents

Legal Events